United TherapeuticsFRA:UTH +1.26%81 Days Payable is 4.79 as of Mar. 2026, which is 73% below its 10-year median of 17.71. GuruFocus rates FRA:UTH with a GF Score™ of 81/100 and a GF Value™ of €336.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, United Therapeutics ranks worse than 99.78% on this metric.
The historical rank and industry rank for United Therapeutics's Days Payable or its related term are showing as below:
FRA:UTH'
s Days Payable Range Over the Past 10 Years
Min: 5.62 Med: 17.71 Max: 51.21
Current: 5.62
During the past 13 years, United Therapeutics's highest Days Payable was 51.21. The lowest was 5.62. And the median was 17.71.
FRA:UTH's Days Payable is ranked worse than 99.78% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:UTH: 5.62
United Therapeutics's Days Payable
declined
from Mar. 2025 (6.11) to Mar. 2026 (4.79).
It may suggest that United Therapeuticsaccelerated paying its suppliers.
United Therapeutics Days Payable Related Terms
United Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
United Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a Days Payable of 4.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on United Therapeutics and its competitors. This is 73% below median its historical median of 17.71. Over the past decade, United Therapeutics' Days Payable has ranged from 5.62 to 51.21. According to the industry distribution chart, United Therapeutics ranks #920 out of 922 companies in the Drug Manufacturers industry, placing it in the top 99.8%.
Is United Therapeutics' Days Payable too high?
United Therapeutics' current Days Payable of 4.79 is 73% below median its 10-year median of 17.71. Over the past 10 years, this metric has ranged from a low of 5.62 to a high of 51.21. The Drug Manufacturers industry median Days Payable is 90.84. United Therapeutics' value of 4.79 is 94.7% below this industry median. Based on the distribution chart, United Therapeutics ranks #920 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, United Therapeutics has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Days Payable compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #920 out of 922 companies for Days Payable. This places United Therapeutics in the lower half of its industry. The industry median Days Payable is 90.84. United Therapeutics' value of 4.79 is 94.7% below this benchmark. Historically, United Therapeutics' own Days Payable has ranged from 5.62 to 51.21 over the past decade. While the company's 10-year median is 17.71 vs. the industry median of 90.84, United Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Days Payable of 4.79 is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Days Payable is 4.79, which is 73% below median its own 10-year median of 17.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €336.05, compared to a current price of €483.30 — trading 43.8% above its estimated fair value. The current Days Payable is 4.79, which is 73% below median its 10-year median of 17.71 and 94.7% below the Drug Manufacturers industry median of 90.84. United Therapeutics' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current Days Payable is 4.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €483.30 is trading 43.8% above its estimated GF Value™ of €336.05.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
Days Payable: 4.79 (73% below median its 10-year median of 17.71)
GF Value™: €336.05 vs. price of €483.30 (43.8% above fair value)
Industry Position: 94.7% below the Drug Manufacturers median (#920 of 922)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
81GF Score
Get the complete analysis for FRA:UTH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
